ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703, which has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702, which has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California, and is a subsidiary of YuanGene Corporation.
| Symbol | ABVC |
|---|---|
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| CEO | Uttam Yashwant Patil |
| Employees | 18 |
| Headquarters | Fremont, CA, US |
| IPO | 2004-11-10 |
| Website | www.abvcpharma.com |